Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida.
Spine (Phila Pa 1976). 2019 Jun 15;44(12):E731-E734. doi: 10.1097/BRS.0000000000002973.
Retrospective outcomes review.
To analyze and report long-term outcomes in a cohort of patients treated with radiotherapy (RT) for symptomatic hemangioma of a vertebral body.
Data are scarce on the rate of tumor control with long-term (>5 yr) follow-up after RT for symptomatic hemangioma of a vertebral body.
We retrospectively reviewed the medical records of patients treated at our institution between 1971 and 2008 for symptomatic hemangioma of a vertebral body, updated their follow-up, analyzed complications, and calculated the tumor control rate. Tumor control by imaging was defined as no increase in tumor size on computed tomography (CT) or magnetic resonance (MR) scan. Clinical tumor control was defined as no symptoms of recurrent tumor.
Ten patients were eligible for analysis. All patients had pain from visible hemangioma at the time of radiotherapy for which surgical resection or interventional radiology procedures were likely to result in high morbidity. Tumors were located in the lumbar (40%), thoracic (50%), or cervical (10%) areas of the spine. The mean radiotherapy dose delivered was 47 Gy.Mean imaging follow-up after completion of radiotherapy was 8.1 years; mean clinical follow-up was 21.2 years. The tumor control rate was 90% (9/10). One patient who may have developed a tumor recurrence had radiographic and clinical evidence of tumor progression 30 years after radiotherapy. The actuarial rate of tumor control was 100% at 5, 10, 20, and 25 years. There was no grade more than or equal to three treatment toxicities, no evidence of malignant transformation, and no evidence of second tumors in treatment area (with the possible exception of the one tumor recurrence).
RT for symptomatic hemangioma of the spine provides long-term tumor control with a low risk of serious complications. Radiotherapy is a good option when surgery or an interventional radiology procedure is high-risk. Our preferred dose is 45 Gy at 1.8 Gy/fraction.
回顾性结果回顾。
分析并报告一组接受放射治疗(RT)治疗症状性椎体血管瘤患者的长期结果。
关于 RT 治疗症状性椎体血管瘤的长期(>5 年)随访后肿瘤控制率的数据很少。
我们回顾性地审查了 1971 年至 2008 年在我们机构接受治疗的症状性椎体血管瘤患者的病历,更新了他们的随访情况,分析了并发症,并计算了肿瘤控制率。影像学肿瘤控制定义为 CT 或磁共振(MR)扫描未见肿瘤增大。临床肿瘤控制定义为无复发性肿瘤症状。
10 名患者符合分析条件。所有患者在接受放疗时均有可见血管瘤引起的疼痛,手术切除或介入放射学治疗可能导致高发病率。肿瘤位于腰椎(40%)、胸椎(50%)或颈椎(10%)脊柱区域。平均放射剂量为 47Gy.Mean 影像学随访时间为放疗后 8.1 年;平均临床随访时间为 21.2 年。肿瘤控制率为 90%(9/10)。一名患者可能发生肿瘤复发,在放疗后 30 年出现影像学和临床证据表明肿瘤进展。肿瘤控制的 5、10、20 和 25 年累积率为 100%。无 3 级以上治疗毒性,无恶性转化证据,治疗区域无第二肿瘤证据(除了一个肿瘤复发)。
RT 治疗脊柱症状性血管瘤可长期控制肿瘤,严重并发症风险低。当手术或介入放射学治疗风险较高时,放疗是一个不错的选择。我们首选的剂量是 45Gy,1.8Gy/次。
4 级。